Association of co-stimulatory human B-lymphocyte antigen B7-2 (CD86) gene polymorphism with colorectal cancer risk

• Published in: Gastroenterology and hepatology from bed to bench 2013, Vol.6 (2), p.86-91
• Main Authors: Azimzadeh, Pedram, Romani, Sara, Mirtalebi, Hanieh, Fatemi, Seyed Reza, Kazemian, Shabnam, Khanyaghma, Mahsa, Mohebbi, Seyed Reza
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2008-2258; 2008-4234

This study investigated the role of CD86 +237 G/C polymorphism in intensifying the risk of CRC development. Colorectal cancer (CRC) is a multi-factorial diseases. Genetic background could affect the susceptibility of individuals to CRC development. CD86 is a co-stimulatory factor on antigen-presenting cells that plays key roles in several cancer related mechanisms such as autoimmunity, transplantation and tumor immunity. A total of 300 individuals, 150 known CRC patients and 150 healthy control individuals, were subjected for the study. CD86 rs17281995 single nucleotide polymorphism (SNP) was genotyped using Allelic Discrimination method. A statistically significant difference was found among CD86 gene polymorphism (rs17281995) and risk of CRC development. The frequency of GG, GC and CC in control subjects was determined as 38%, 57.3% and 4.7% respectively and in CRC subjects were determined as 42%, 85% and 23% respectively. The data shows a significant association between CC genotype (P = 0.007) and C allele (P = 0.017) of the studied polymorphism and risk of CRC. CC genotype and C allele are also more frequent in female patients when the data is stratified according to gender status. Our results suggest that CD86 gene alteration could affect the individual's risk for developing CRC among Iranian population and could be used as an important prognostic factor associated with risk of CRC.